|
Aug 7
|
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
|
|
Jul 31
|
Insiders Favor These 3 High Growth Companies
|
|
Jul 30
|
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
|
|
Jul 29
|
Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late?
|
|
Jul 29
|
Relay Therapeutics has positive read from Celcuity data, says Barclays
|
|
Jul 29
|
Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial
|
|
Jul 28
|
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
|
|
Jul 28
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jul 28
|
Celcuity stock rallies on Phase III breast cancer trial progress
|
|
Jul 28
|
Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More
|
|
Jul 28
|
Celcuity Stock Triples on Positive Breast Cancer Treatment Study
|
|
Jul 28
|
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer
|
|
Jul 28
|
Trade Outlook Buoys US Equity Futures Pre-Bell
|
|
Jul 28
|
Celcuity shares triple on late-stage results for breast cancer therapy
|
|
Jul 28
|
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
|
|
Jul 25
|
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
|
|
Jul 24
|
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer
|
|
Jul 14
|
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
|
|
Jun 30
|
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
|
|
May 21
|
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
|